echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Phase 3 clinical results of GSK/Medicago new crown plant-derived adjuvant vaccine candidate announced

    Phase 3 clinical results of GSK/Medicago new crown plant-derived adjuvant vaccine candidate announced

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    GlaxoSmithKline (GSK) and Medicago recently announced that the COVID-19 plant-derived vaccine candidate added with GSK pandemic adjuvant has achieved positive results in its efficacy and safety in the global phase 3 placebo-controlled efficacy study


    The vaccine's efficacy has been proven in an environment dominated by SARS-CoV-2 variants, which is different from most of the published Phase 3 trials


    During the study period, no related serious adverse events were reported, and the reactogenicity was generally mild to moderate and transient; the symptoms lasted only one to three days on average


    Based on these results, Medicago will immediately seek registration approval from Health Canada as part of its rolling application


    Medicago has initiated the registration and application procedures for plant-derived adjuvant new coronary pneumonia vaccine candidates in the US FDA and UK MHRA


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.